Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer, announced results of two new real-world studies confirming the positive benefit-risk profile of XARELTO® (rivaroxaban) in treating venous thromboembolism (VTE), or...
Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer, announced results of two new real-world studies confirming the positive benefit-risk profile of XARELTO® (rivaroxaban) in treating venous thromboembolism (VTE), or...
Janssen Pharmaceuticals, Inc....